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is disrupted in Rett syndrome and autism
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Mutations in MECP2, encoding methyl-CpG-binding protein 2 (MeCP2), cause the neurodevelopmental dis-
order Rett syndrome (RTT). Although MECP2 mutations are rare in idiopathic autism, reduced MeCP2
levels are common in autism cortex. MeCP2 is critical for postnatal neuronal maturation and a modulator
of activity-dependent genes such as Bdnf (brain-derived neurotropic factor) and JUNB. The activity-
dependent early growth response gene 2 (EGR2), required for both early hindbrain development and
mature neuronal function, has predicted binding sites in the promoters of several neurologically relevant
genes including MECP2. Conversely, MeCP2 family members MBD1, MBD2 and MBD4 bind a methylated
CpG island in an enhancer region located in EGR2 intron 1. This study was designed to test the hypothesis
that MECP2 and EGR2 regulate each other’s expression during neuronal maturation in postnatal brain devel-
opment. Chromatin immunoprecipitation analysis showed EGR2 binding to the MECP2 promoter and MeCP2
binding to the enhancer region in EGR2 intron 1. Reduction in EGR2 and MeCP2 levels in cultured human
neuroblastoma cells by RNA interference reciprocally reduced expression of both EGR2 and MECP2 and
their protein products. Consistent with a role of MeCP2 in enhancing EGR2, Mecp2-deficient mouse cortex
samples showed significantly reduced EGR2 by quantitative immunofluorescence. Furthermore, MeCP2
and EGR2 show coordinately increased levels during postnatal development of both mouse and human
cortex. In contrast to age-matched Controls, RTT and autism postmortem cortex samples showed significant
reduction in EGR2. Together, these data support a role of dysregulation of an activity-dependent EGR2/
MeCP2 pathway in RTT and autism.
INTRODUCTION
Rett syndrome (RTT) and autism fall within the five pervasive
developmental disorders (PDDs) described in the Diagnostic
and Statistical Manual of Mental Disorders (1). Clinical fea-
tures of RTT include autistic features, mental retardation, pos-
tural hypotonia, difficulties in locomotion, loss of purposeful
hand use, stereotyped hand movements, progressive scoliosis,
seizures, and autonomic nervous system disturbances (2–4).
RTT patients also suffer from respiratory abnormalities includ-
ing hyperventilation, breath-holding, apnea and air swallowing
as well as feeding problems characterized by poor tongue mobi-
lity and difficulties in swallowing of food (5,6).
RTT is an X-linked dominant PDD caused by mutations in
methyl CpG-binding protein 2 (MECP2) (7). MeCP2, which
binds methylated CpGs, is a chromatin-associated protein (8)
which can both activate and repress transcription (9,10).
Required for maturation of neurons, MeCP2 is developmen-
tally regulated in both human and mouse (11–13). Although
MECP2 mutations cause RTT in females, milder mutations
and duplications of MECP2 have been found in males with
mental retardation (14,15). Reduced MeCP2 expression in
brain has been observed in 79% of autism cortex samples
(16) and functional variants of the MECP2 gene may confer
autism vulnerability (17). A hypomorphic allele of Mecp2
in a transgenic mouse model also shows abnormal social
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behavior (18,19) further implicating reduced MeCP2
expression in autistic behavior.
The maturation of neuronal networks involves translation of
sensory experience into synaptic connectivity mediated by
activity-dependent gene transcription (20–22). Many of the
characteristics of the RTT phenotype involve defects in the
processes which rely upon this activity-dependent maturation
program including dendritic branching, synaptic plasticity,
memory and learning and inhibitory circuits (22). Activity-
dependent gene cascades underlying these processes are
often triggered by neuronal activity followed by calcium
influx and a related protein phosphorylation event (23).
Immediate early genes (IEGs), a class of activity-dependent
genes, are rapidly and transiently induced by neuronal acti-
vation and other cellular or extra-cellular stimuli without the
necessity for de novo protein synthesis (24,25). IEGs can be
classified into two categories, ‘effector IEGs’ such as brain-
derived neurotropic factor (BDNF) which play a direct func-
tional role at the synapse and ‘regulatory IEGs’ which for
the most part consist of inducible transcription factors includ-
ing c-Fos, JunB, and the EGR family (26,27).
There is some evidence that activity-dependent gene
expression pathways are disrupted in RTT. Several IEGs
have been identified as actual or potential MeCP2 targets
including JUNB (9), EGR1 (28), and Bdnf (21,22,29).
Recently it was shown that MeCP2 binds the JUNB promoter
when the gene is transcriptionally active (9). In Zhou et al.
(22), activity-dependent phosphorylation of MeCP2 at serine
421 correlated with the transcriptional induction of Bdnf.
Interestingly, double mutants of Bdnf and Mecp2 have a
more severe RTT phenotype while overexpression of Bdnf in
Mecp2-deficient mice extends life and improves motor deficits
(30). It was shown in 2006 that both embryonic and adulthood
ablation of Bdnf reduced transcription of Egr2 (early growth
response gene 2) and its sister gene, Egr1 (31).
EGR2 encodes a zinc finger transcription factor observed in
both the somata and dendrites of central neurons (32). EGR2
plays an important role in the transient formation of hindbrain
developmental compartments or rhombomeres and is also an
important factor in peripheral myelination, maintenance of
synaptic plasticity and long-term potentiation (33–37).
Recently, EGR2 was described as the most downregulated
gene in lymphoblastoid cell lines from five monozygotic
twin sets discordant with respect to severity of autism and/or
language impairment suggesting that EGR2 might play a
role in the development of autism (38). To further study the
role of MeCP2 in IEG regulation, we investigated EGR2/
EGR2 as a potential target and transcriptional regulator of
MeCP2. Here we show the reciprocal binding and
co-regulation of MeCP2 and EGR2 and demonstrate that
EGR2 is significantly reduced in Mecp2-deficient mouse as
well as human RTT and autism brain.
RESULTS
ChIP reveals reciprocal binding of MeCP2 to the EGR2
intron and EGR2 to the MECP2 promoter
Since an intronic sequence of EGR2 has previously been
shown to be a binding site for MBDs (methyl-binding
domains) 1, 2 and 4 (39), this region was further explored as
a potential regulatory target for MeCP2. Because of a
suggested role of MeCP2 in the matrix attachment of chroma-
tin loop structures (40) a bioinformatics search for matrix
attachment regions (MARs) (41) was conducted using
MAR-Wiz, identifying a 900 bp region within the EGR2
intron (EGR2 contains only one intron) with strong binding
potential (Supplementary Material, Fig. S1). To directly test
whether MeCP2 bound to this EGR2 regulatory sequence in
neuronal cells, chromatin immunoprecipitation (ChIP) with
MeCP2-specific antibodies was conducted on chromatin
from 48 h PMA(phorbol ester)-stimulated SH-SH5Y neuro-
blastoma cells, a system previously demonstrated to show
increased MeCP2 levels (42). Quantitative polymerase chain
reaction (qPCR) using primers designed to the EGR2 intron
showed significant enrichment of MeCP2 ChIP fragments at
this site compared with a Control ChIP experiment using a
non-specific antibody in the place of the anti-MeCP2 antibody.
(Fig. 1A).
The MECP2 promoter sequence was examined for potential
EGR2-binding sites using TESS (transcriptional element
search string) (43). A highly conserved site located between
the core promoter (44) and the transcriptional start site of
MECP2 (Supplementary Material, Figs S2 and S3) was
Figure 1. (A) ChIP using anti-MeCP2 or non-specific IgY was performed on
chromatin from PMA-stimulated human neuroblastoma cells in two separate
experiments. qPCR was performed using primers designed to a DNA sequence
in the EGR2 intron which contains a putative MAR and CpGs in the vicinity of
A/T runs (diagrammed above). MeCP2 ChIP was significantly enriched com-
pared with the IgY Control ChIP normalized to one (P , 0.03 by Wilcoxon).
Results are the mean+SEM of six replicates. (B) ChIP was performed using
anti-EGR2 or non-specific IgG and primers were designed to a region between
the MECP2 core promoter and transcriptional start site which contained a pre-
dicted EGR2-binding site (diagrammed above). EGR2 ChIP was significantly
enriched compared with the RIgG Control ChIP normalized to 1 (P, 0.02 by
Wilcoxon). Results are the mean+SEM of seven replicates. Both the exper-
imental and the Control ChIP experiments were normalized to input.
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tested for enrichment of EGR2 binding by ChIP (Fig. 1B).
EGR2 binding to the MECP2 promoter also revealed signifi-
cant enrichment compared with the non-specific IgG Control
by ChIP (Fig. 1B). Positive Controls for known MeCP2 and
EGR2-binding sites, SNRPN (45) and MBP (myelin basic
protein) (46) respectively, showed expected enrichment com-
pared with the appropriate non-specific antibody Controls
(Supplementary Material, Fig. S4).
Reciprocal siRNA knockdown of EGR2 and MECP2
MeCP2 expression increases during maturation of neurons, a
process that can be modeled by stimulation of human
SH-SY5Y neuroblastoma cells with PMA. Both MECP2 and
EGR2 protein showed 2-fold upregulation within 20 h of
PMA treatment for EGR2 and 68 h after PMA treatment for
MeCP2 when measured by immunofluorescence and laser
scanning cytometry (LSC) (Supplementary Material,
Fig. S5). To test a potential co-regulatory relationship
between EGR2 and MECP2, siRNAs specifically targeting
MECP2 and EGR2 were transfected into SH-SY5Y cells,
revealing a pattern of reciprocal knockdown. Transfection
with EGR2 siRNA resulted not only in reduction in EGR2
protein and EGR2 transcript as measured by immunofluores-
cence and LSC or qPCR, respectively (Fig. 2A and Sup-
plementary Material, Fig. S6A), but also a significant
reduction in MeCP2 protein and MECP2 transcript compared
with Controls, measured by LSC and qPCR (Fig. 2B and Sup-
plementary Material, Fig. S6B). Conversely, transfection with
MECP2 siRNA resulted not only in reduction in MeCP2
protein and MECP2 transcript (Fig. 2A and Supplementary
Material, Fig. S6C) but also a significant reduction in EGR2
protein and EGR2 transcript compared with Controls,
measured by LSC and qPCR (Fig. 2D and Supplementary
Material, Fig. S6D). Reciprocal knockdowns were also
observed in cells which were transfected with siRNA but not
stimulated with PMA (data not shown).
Developmental expression profile of MeCP2 and EGR2
A mouse tissue array containing cores of cortical tissue from
wild-type C57BL/6J mice at a variety of prenatal, perinatal,
and postnatal timepoints, was immunofluorescently stained
for MeCP2 and EGR2 protein and fluorescence was quantified
to determine the developmental ontogeny of MeCP2 and
EGR2 in mouse cortex. This analysis revealed a rise in the per-
centage of cells with high EGR2, beginning at embryonic
(E19) and reaching a plateau at postnatal day 7 (P7) for
EGR2 and a more gradual rise from 1 to 10 weeks of age
for MeCP2 (Fig. 3A). The overall levels of both EGR2 and
Figure 2. Reciprocal siRNA transfections were performed on SH-SY5Y
human neuroblastoma cells then stimulated 4 h later with PMA. 48 and 72 h
post-transfection EGR2 and MeCP2 protein levels were quantified by immu-
nofluorescence and LSC. Results are shown for the optimal timepoint of
knockdown for EGR2 (48 h) and MeCP2 (72 h), but all timepoints were
assayed for transcript levels for MECP2 and EGR2 (Supplementary Material,
Fig. S6) and protein levels showed similar results at both timepoints (data not
shown). All results are shown as the mean+SEM of three replicates with the
mean Control normalized to 100%. (A) SH-SY5Y cells were transfected with
EGR2 siRNA (light gray bars) or Control (black bars) and show reduced
EGR2. (B) Cells transfected as in ‘A’ were also tested for MECP2 transcript
by qPCR and MeCP2 protein by LSC. (C) SH-SY5Y cells were transfected
withMECP2 siRNA (light gray bars) or Control (black bars), showing specific
knockdown of MeCP2 levels. (D) Cells transfected as in ‘C’ showed reduced
EGR2 transcript by qPCR and EGR2 protein by LSC.
Figure 3. LSC analysis of immunofluorescence for MeCP2 and EGR2 on a
mouse developmental tissue microarray. Expression patterns in the mouse
cortex show increasing levels of both MeCP2 and EGR2 during development.
(A) In order to determine the percent of high-expressing cells in the mouse
cortex, cell populations with high and low EGR2 or MeCP2 protein levels
were differentiated by gating an LSC histogram for the youngest cerebral
cortex postmortem sample (E15) at the right half-maximum. (B) Mean
MeCP2 or EGR2 protein in the mouse cortex was determined by measuring
the mean fluorescence value (mean maximum pixel) for all cortical cells at
each developmental timepoint.
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MeCP2 showed gradual, coordinated increases in postnatal
brain with age (Fig. 3B). MeCP2 and EGR2 were colocalized
in neurons, but EGR2 staining was both nuclear and cyto-
plasmic, as has been previously reported (32).
In order to further test the hypothesis that EGR2 might be
involved in regulatory pathways relevant to RTT, a tissue
microarray containing triplicate 600 mm cores of cortical
tissue from a mouse model of RTT (Mecp2tm1Bird/y) and
wild-type C57BL/6J littermate Controls for six age-matched
timepoints (P7, P28, P35, P49, P56 and P70) was immuno-
fluorescently stained for MeCP2 and EGR2 and analyzed by
LSC (Fig. 4). Analysis of the array showed significantly
decreased EGR2 expression in Mecp2tm1Bird/y cortical cells
for all mutant cortical core samples compared with all wild-
type core samples at all timepoints (P, 0.00005, Fig. 4C).
Reductions in EGR2 were most apparent in Mecp2-deficient
cortical cells at the P28 timepoint (Fig. 4D). Furthermore,
follow-up staining of sagittal brain sections from P28 wild-
type (C57BL/6J) and Mecp2-null (Mecp2tm1Bird/y) mice con-
firmed significantly decreased EGR2 in multiple areas of the
brain, including medulla, cerebellum and pons (Supplemen-
tary Material, Fig. S7).
EGR2 increases developmentally in postnatal human
cortex and is downregulated in RTT and autism cortex
To test the hypothesis that EGR2 expression is dysregulated in
human RTT and autism brain, LSC analysis of EGR2 and
MeCP2 immunofluorescence on a human tissue microarray
containing triplicate cortical samples from individuals with
RTT, autism or other neurodevelopmental disorders was exam-
ined and compared with age-matched typically developing
Controls. Similar to mouse cortex, EGR2 immunofluorescence
colocalized with MeCP2 staining in human cortical neurons
(SupplementaryMaterial, Fig. S8). Analysis of human develop-
mental EGR2 expression showed that, as in the mouse, MeCP2
and EGR2 are developmentally increased over postnatal life-
span in typically developed (TD) cortex (Fig. 5). More specifi-
cally, a steady increase in the number of EGR2-high cells from
the age of 20 days to 18 years was observed (Fig. 5A). Group
comparison of TD, RTT and autism samples (RTT/TD and
AUT/TD) spanning childhood to adult years showed a statisti-
cally significant downregulation of EGR2 in RTT (P , 0.005
by t-test) and AUT brain (P , 0.00005 by t-test) (Supplemen-
tary Material, Table S1). A comparison of each individual
RTT or AUT sample to its three closest age-matched TD
Figure 4. EGR2 Expression is dysregulated in Mecp2tm1Bird/y mouse cortical
cells. Four replicate tissue microarrays containing triplicate cores from wild-
type male or Mecp2 tm1Bird/y mouse cortex at six postnatal timepoints (P7,
P28, P35, P49, P56 and P70) were stained using antibodies recognizing
EGR2 and MeCP2. The arrays were gated for MeCP2 expression (A) or
EGR2 expression (B). Individual cells (pixels) colored darkly represent high
MeCP2 or EGR2 staining, defined as the right half-maximum of the histogram.
(C) In a representative histogram, decreased EGR2 was detected by immuno-
fluorescence and LSC in the Mecp2tm1Bird/y cortical cells for the group of six
Mecp2tm1Bird/y mice in the array (black histogram) compared with all six Con-
trols grouped (white histogram) (P, 0.00005 by x2). (D) Differences were
most apparent at P28 in wild-type male cortical cells (white histogram) com-
pared withMecp2 tm1Bird/y cortical cells (black histogram) (P , 0.0001 by x2).
Figure 5. LSC analysis of MeCP2 and EGR2 immunofluorescence on a human
tissue microarray. Human cortical cells (Brodmann Area 9) show increasing
levels of both MeCP2 and EGR2 during development. (A) In order to deter-
mine the percent of high-expressing cells in the human cortex, cell populations
with high and low MeCP2 or EGR2 protein levels were differentiated as in the
mouse cortex. The high- and low-expressing cell populations were gated on
the right-half maximum of the histogram for the youngest age and this gate
was used for all subsequent ages. (B) Mean MeCP2 or EGR2 protein
expression in the human cortex was determined by measuring the mean fluor-
escence value (mean maximum pixel) at each age examined.
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Control samples also showed that EGR2 was dysregulated in a
subset of samples, with a statistically significant downregula-
tion of EGR2 observed in both RTT and AUT brain (Sup-
plementary Material, Table S1). A non-parametric analysis
similarly demonstrated statistically significant EGR2 downre-
gulation in RTT and AUT brain as the means were outside a
95% confidence interval (Fig. 6D). As previously observed
(16,47) MeCP2 was also significantly reduced in autism brain
(Supplementary Material, Table S1).
DISCUSSION
In this study, we have used a candidate approach for activity-
dependent early activation transcription to identify a new
MeCP2 target gene, EGR2. As an IEG, EGR2 is increased
rapidly in response to neuronal activity. Here we show evi-
dence that EGR2 positively regulates MECP2 by binding to
its promoter, and in turn, MeCP2 binds to an enhancer of
EGR2, further upregulating expression of both genes in a posi-
tive feedback loop for increased neuronal maturation. In vivo
we have established that developmental upregulation of
EGR2 parallels the developmental ontogeny of MeCP2 and
that EGR2 is dysregulated in an animal model of RTT as
well as in human RTT and MeCP2-deficient autism brain.
The EGR genes have recently been implicated in a number
of neuropsychiatric or neurodevelopmental conditions includ-
ing schizophrenia (48,49) depression (50), dysregulated stress
response (49,51), aggression (49) and autism (38). EGR2 may
play a novel role in cognitive functions associated with atten-
tion, an executive function with which autistic individuals
often experience difficulty (37,52,53). Our results are consist-
ent with a role of EGR2 in autism spectrum and neurodevelop-
mental disorders.
The EGR family of transcription factors are able to mediate,
amplify or modulate the impact of downstream gene expression
patterns. EGR family genes are responsive to both cellular and
environmental stimuli such as triazole (54), progesterone (55),
stress (56), seizures (57) and valproic acid (58). Interestingly,
perinatal exposure to valproic acid is a known risk factor for
autism (59–62). EGR2 is involved in brain development
(63–65), myelination and routing of axons (66,67). Our
results provide a role of EGR2 in MeCP2 regulation and
suggest that the postnatal developmental ontogenies of EGR2
and MeCP2 are interrelated. One alternative explanation for
the reciprocal regulation of MeCP2 and EGR2 in siRNA exper-
iments could be simply a delay of maturational differentiation
of SH-SY5Y cells with either factor acting through an indirect
versus direct pathway. However, the observation of direct
binding of MeCP2 to EGR2 and EGR2 to MECP2 by ChIP
in the same cell line supports a model of direct interactions in
addition to indirect pathways such as the Mecp2/Bdnf/Egr2
pathway previously described (31).
Since EGR2 is a regulator of many neurologically relevant
genes, disruption of normal EGR2 expression has the potential
to influence many downstream targets. Previously identified
neurologically relevant EGR2 targets include EGR2 itself;
the NAB genes whose protein products interact with EGR2
to repress gene expression; inhibition of differentiation
genes, ID2 and ID4, as well as a number of HOX genes
(68–71). Interestingly, ID2 and ID3 are also targets of
MeCP2 (72) and homozygous mutations in HOXA1 were
observed in familial pedigrees with autism (73), further impli-
cating these regulatory pathways in autism spectrum disorders.
More recently, homozygosity mapping of multiple recessive
autism pedigrees revealed that a number of genes regulated
by neuronal activity may be implicated in autism (74).
Although MeCP2 was once predicted to be solely a tran-
scriptional repressor of genes with methylated CpG island pro-
moters, more recent genomic analyses have established that
the primary function of MeCP2 is not the silencing of methyl-
ated promoters (9,10). To the contrary, the majority of
MeCP2-bound promoters are actively expressed (9) and more
transcripts are upregulated by increasing Mecp2 genetic
dosage than downregulated (10). Interestingly, genomic ChIP
analyses showed that the majority of the intragenic
Figure 6. Immunohistochemical analysis by LSC of a human postmortem
brain cortical array including samples from TD, RTT and autism brain.
EGR2 was significantly lower in both RTT and autism brain samples.
(A) Representative histogram showing higher EGR2 expression (dark histo-
gram) in TD cortex compared with EGR2 expression in RTT cortex (light his-
togram). (B) Representative histogram showing higher EGR2 expression (dark
histogram) in TD cortex compared with EGR2 expression in autism cortex
(light histogram). (C) Boxplot of EGR2 fluorescence (maximum pixel) nor-
malized to housekeeping Control (Histone H1) with comparisons made
between Control (n ¼ 13), RTT (n ¼ 10) and autism (n ¼ 13). Boxplot of
EGR2 in TD, RTT and autism cortex. (D) Statistical analysis showed non-
overlapping 95% confidence intervals for the TD, RTT and autism samples
and downregulation of EGR2 in RTT and autism brain (see Supplementary
Material, Table S1 for additional analyses).
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MeCP2-binding sites were intronic (9). In the context of EGR2
regulation this is not surprising, as earlier researchers demon-
strated that other members of the MBD family-bound methyl-
ated CpGs within the EGR2 intron examined here (39). These
results are also consistent with regulation of GABRB3, where
MeCP2 binds to an intronic methylated sequence and pro-
motes rather than represses expression (75).
As a result of our study, we propose that EGR2 and MeCP2
have the ability to facilitate each other’s postnatal develop-
mental expression. At critical developmental stages, intra- or
extra-cellular stimuli induce expression of EGR2 or MeCP2
each of which can bind the appropriate site, near the
MECP2 core promoter in the case of EGR2, or the EGR2
intron in the case of MeCP2, enhancing the expression of its
regulatory partner in a positive feedback loop. This positive
feedback mechanism may serve to fine-tune the genomic
response to a variety of environmental stimuli.
Dysregulation of this feedback system may play a role in the
defects associated with autism spectrum disorders, with loss or
reduction in functional MeCP2 decreasing the responsiveness
of EGR family members and other IEGs to stimuli which
induce the maturation of neuronal networks in typical cortical
development. Our human brain analyses support the hypoth-
esis that RTT and autism are disorders of stalled or arrested
maturational brain development (76,77) as EGR2 levels in
adult RTT and autism brain are lower than expected for
their age. These results also suggest the possibility that
increasing neuronal stimuli postnatally may partially
improve the maturational defects of RTT and autism. In
support of this premise, recent studies showed environmental
enrichment could ameliorate motor coordination deficits in a
mouse model of RTT (78,79) and evidence suggests that
early behavioral interventions have a positive effect on
autism outcomes (80). A number of clinical trials involving
autistic patients are examining the effects of aripiprazole
(Abilifyw, Bristol-Myers Squibb), an atypical antipsychotic
which may upregulate EGR2 (81, http://clinicaltrials.gov/ct2/
results?term¼autismþaripiprazole). Further examination of
EGR2 and other IEGs in relation to autism spectrum disorders,
including RTT, should be undertaken as part of the search for
treatment strategies, including environmental enrichment and
new pharmacological interventions.
MATERIALS AND METHODS
Cell lines
SH-SY5Y human neuroblastoma cells (American Type
Culture Collection) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 15% fetal bovine serum
(Gibco), MEM NEAA (Gibco), 10 mM Hepes pH 7.3
(Gibco) and 2-mercaptoethanol (Gibco). Cells for ChIP were
grown to 70–80% confluency in T175 cm2 flasks and cells
for RNA interference (RNAi) were grown in two-chamber
slides coated with poly-D-lysine (Sigma) or six-well plates.
RNA interference
siRNAs specifically targeting MECP2 and EGR2 were pur-
chased from Dharmaconw (Supplementary Material,
Table S2). Transfection of a pool of these siRNAs was con-
ducted in six-well plates and two-chamber slides using
DharmaFECT1w transfection reagent. SH-SY5Y cells were
incubated at 378C in 5% CO2. The media formulation con-
tained Gibco MEM with Earle’s salts supplemented by non-
essential amino acids (1% final concentration), Hepes buffer
(1% final concentration) and beta-mercaptoethanol (0.5%
final concentration). Cells were cultured with no antibiotics
present in the media. When cells reached 70–80% confluence,
they were trypsinized and seeded in the six-well plates and
chamber slides at 2.5  104 cells per well or chamber and
incubated overnight at 378C. The next day, treated cells
were transfected using DharmaFECT1w siRNA transfection
reagent and either no siRNA, EGR2 siRNA, MECP2 siRNA,
a non-targeting Control siRNA or DharmaFECT1w only.
Transfections were conducted according to the manufacturer’s
general transfection protocol. Four hours after the transfection,
the cells were stimulated to differentiate by the addition of
PMA to a final concentration of 160 nM per well or
chamber. Twenty-four hours after the first siRNA transfection,
a second transfection was performed. Separate aliquots of
untreated cells and aliquots of cells which were transfected
with siRNA but not stimulated with PMA were cultured in
parallel as additional Controls.
cDNA synthesis and qPCR
qPCR was performed with a LightCycler (Roche, Indianapolis,
IN, USA) according to manufacturer’s instructions. Primers
for EGR2, MECP2 and GAPDH were designed using
primer3 software with one of the primers of each primer
pair spanning an intron–exon junction so as not to amplify
genomic DNA (Supplementary Material, Table S3). Primer
pairs were analyzed with BLAST to verify that the sequences
were unique to the appropriate amplicon. PCR reactions
include 1X DNA master SYBR Green I reaction buffer
(Roche), 1.5–2 mM MgCl2, 0.5 micromolar of primers and
10–20 ng of cDNA or ChIP DNA. In the case of RNAi exper-
iments, total RNA was extracted from SH-SY5Y cells in
culture using the RNeasy Mini Kit (Qiagen) and cDNA was
synthesized using a QuantiTect Reverse Transcription kit
(Qiagen). Melting curve analysis was conducted to confirm
specificity of the amplicon. Quantitation was conducted
using the comparative CT method (Applied Biosystems) and
is reported as n-fold difference, relative to a calibrator, follow-
ing normalization to GAPDH or input DNA in the case of
ChIP PCR.
Sequence analysis
A search for possible MeCP2-binding sites in the EGR2 intron
and EGR2-binding sites in MECP2 regulatory regions was per-
formed using MAR-Wiz (Futuresoft at http://www.futuresoft.
org/MAR-Wiz/) and TESS (43, http://www.mrw.interscience.
wiley.com/emrw/9780471250951/cp/cpbi/article/bi0206/
current/pdf). The MeCP2 homolog in chicken, ARBP,
recognizes MARS. MARs, DNA sequences which bind to
the nuclear matrix, may function as anchoring sites for
higher order chromatin structures including loops (41,82).
Because other members of the MBD family bind a region in
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the EGR2 intron (39), this same region was examined for
MeCP2-binding potential. MAR-Wiz analysis of the EGR2
intron revealed a high-scoring putative MAR with an
average MAR potential or strength of 0.83 (Supplementary
Material, Fig. S1). This same region also contained CpGs in
the vicinity of A/T runs which are a prerequisite for MeCP2
binding (Supplementary Material, Fig. S1) (83). The
sequences of predicted EGR2 sites were confirmed by com-
parison with potential EGR2-binding sites defined in (84) or
(85). TESS predicted EGR2-binding sites in the MECP2 pro-
moter region and in an enhancer sequence, identified by Liu
and Francke (44), within the MECP2 30-UTR (Supplementary
Material, Fig. S2). The predicted EGR2-binding site located in
the MECP2 promoter region is highly conserved (Supplemen-
tary Material, Fig. S3A) whereas the predicted site in the
MECP2 30-UTR is not (Supplementary Material, Fig. S3B).
ChIP and qPCR for ChIP
Chromatin from PMA-stimulated SH-SY5Y cells was isolated
as described previously with some modifications (45,72). For
each experiment, 150–200 mg of chromatin were digested
into 300–500 bp fragments with HindIII, SpeI and SphI
(New England Biolabs) and precleared by incubation with
agarose beads (PrecipHen agarose, Aves labs or protein A/G
agarose, Pierce) followed by incubation with the appropriate
preimmune serum (chicken IgY or rabbit IgG) and a second
incubation with agarose beads. Precleared chromatin was
divided (40 mg per tube) and incubated overnight with an
excess of C-terminal anti-MeCP2 (raised in chicken to the
C-terminal peptide N-RPNREEPVDSRTPVTERVS-C, Aves
labs); preabsorbed IgY as a Control for non-specific binding;
anti-EGR2 (Santa Cruz) or rabbit IgG Control. Antibody incu-
bations were followed by additional incubation for 4–6 h with
the appropriate agarose beads as described earlier. An aliquot
of precleared chromatin was set aside as total input Control.
Immunoprecipitates were collected by centrifugation, washed
and digested with 50 m/ml DNase free RNase A for 30 min
at 378C, followed by SDS/proteinase K digestion and sub-
jected to phenol/chloroform extraction prior to ethanol precipi-
tation with glycogen.
qPCR was performed using a Lightcycler (Roche, Indiana-
polis, IN, USA) according to the manufacturer’s instructions.
Primer sequences specific to the MECP2 core promoter, the
MECP2 enhancer region, the EGR2 intron, a known EGR2-
binding site and an MeCP2-binding site near the SNRPN
gene are listed in Supplementary Material, Table S3. Primer
sequences were designed to be compatible with the restriction
enzyme cocktail used to digest the chromatin. The data were
analyzed by LightCycler software version 2.0. Final quantifi-
cation was performed using the comparative CT method
(Applied Biosystems) and is reported as the n-fold difference
in input-normalized, antibody-precipitated chromatin relative
to input-normalized serum-incubated chromatin.
Tissue microarrays
A mouse developmental tissue array, including triplicate
600 mm cores of brain cortical tissue from wild-type
C57BL/6J and Mecp2tm1Bird/y for a number of age-matched
timepoints including P7, P28, P35, P49, P56 and P70, was
fixed and embedded in paraffin as previously described (72).
A second mouse tissue microarray, created in a similar
manner, contained wild-type male and female as well as
Mecp2tm1Bird/y and Mecp2tm1Bird/þ cortical cores for age-
matched timepoints including E15, E19, P7, P21, P35 and
P70 was also fixed and embedded in paraffin.
Human brain tissue array
The human brain tissue array including triplicate 600 mm
diameter tissue cores were extracted and processed as
described previously from cerebral cortical samples (layers
III–IV of Brodmann Area 9) and fusiform gyrus samples
(Nagarajan et al., 2006). Immunofluorescence was performed
on tissue microarray slides with anti-MeCP2 and anti-EGR2
antibodies and the slides were scanned by LSC. Fluorescence
was normalized to histone H1 as previously described (12).
Triplicate cores for each disorder and TD Controls were ana-
lyzed for each experimental replicate and mean normalized
MeCP2 and EGR2 fluorescence was calculated for each
tissue core in three replicate arrays (N ¼ 9). Normalized
immunofluorescence for each disorder sample was compared
with that of the three closest, age-matched Controls (n ¼ 27)
and statistical significance was determined by t-test. Group
comparisons were also conducted and statistical significance
for these comparisons was determined by t-test.
Immunofluorescence and LSC
LSC shares some similarities with flow cytometry in its ability
to quantitate fluorescence of individual cells. However, with
LSC solid-phase samples such as adherent cultured cells,
tissue sections and cytology smears can be examined for
genetic, biochemical or morphological properties (http://
www.compucyte.com/laserscanning.htm). Here, paraffin-
embedded tissue microarrays (human or mouse) or sagittal
brain hemispheres (mouse) were cut into 5 mm sections,
placed on glass slides and stained as previously described
(72). Primary antibodies used were: anti-EGR2 (Santa Cruz,
rabbit polyclonal), 1:100, anti-MeCP2 (Aves, C-terminal,
chicken polyclonal) 1:1000 and anti-Histone H1 (Upstate,
mouse polyclonal) 1:100. The anti-Mecp2 Aves, C-terminal
chicken polyclonal detects both the E1 and E2 isoforms of
MeCP2. Secondary antibodies used were: goat anti-rabbit
IgG-Oregon Green (Molecular Probes) 1:100, donkey
anti-chicken IgG-Cy5 and goat anti-mouse IgG-Cascade
Blue (Molecular Probes) 1:100. Rabbit IgG (Upstate),
Chicken IgY (Aves) and Mouse IgG (Upstate) were used on
Control slides with the same secondary as the experimental
slides to test for background levels of staining or immuno-
fluorescence. Replicate slides were stained and scanned by
LSC to increase the power of our statistical analyses.
The procedure used for staining cultured neuroblastoma
cells on chamber slides was similar to the procedure for stain-
ing tissue with a few exceptions. Chamber slides were washed
in 1X PBS, placed in HistoChoice (Amresco) for 10–15 min
followed by 1X PBS/Tween 0.02% for 4 min then placed in
70% ethanol for 10 min or for storage at 2208C. Slides to
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be stained were first rinsed in 1X PBS then stained as with the
tissue arrays or sagittal brain sections above.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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